Substance P

PreclinicalSmall molecule

GSK

Substance P is one of 88 small molecule programs targeting Headache. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AngioedemaActive, not recruiting

MigraineActive, not recruiting

ARTCompleted

AngioedemaPreclinical

Active, not recruiting

MigrainePreclinical

Active, not recruiting

ARTPreclinical

Completed

Competition

Competitive Landscape

102 competitors in Migraine

#DrugCompanyPhaseTrials

Avicel

SSanthera Pharmaceuticals

Phase 3

2 2

Magnesium

SSpherium Biomed

Phase 3

3 3

Triptans

Pfizer

Phase 3

2 4

Aspirin /d

TThe First Affiliated Hospital with Nanjing Medical University

Phase 3

1 5

Flunarizine

AAspartes Pharmaceuticals, Inc.

Phase 3

9 6

BAT7104

Teva

Phase 3

1 7

Tizanidine Hydrochloride

EElan Pharmaceuticals

Phase 3

1 8

Bayer Aspirin

Bayer

Preclinical

2 9

Cervidil

Pfizer

Preclinical

1 10

Cymbalta

Jazz Pharmaceuticals

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

N/ARecruiting

Migraine

NCT06959004

Clinical

Trials by Indication[1]

Headache1 trial

Effects of Substance P on Headache Induction in Healthy Individuals

Not yet recruiting·DDanish Headache Center·N/A·NCT06632080·21 enrolled

Angioedema1 trial

Pharmacogenetics of Ace Inhibitor-Associated Angioedema

Completed·VVanderbilt University·N/A·NCT01413542·44 enrolled

Type 1 Diabetes1 trial

Neuropeptide Therapy of Recent Onset Type 1 Diabetes

Unknown status·VVanilloid Genetics Inc.·Phase 1·NCT02820558·12 enrolled

Migraine1 trial

Substance P-Induced Migraine Attacks Without Aura

Recruiting·DDanish Headache Center·N/A·NCT06959004·21 enrolled

Antibody1 trial

Reduction of IgE Antibody in Human Allergic Subjects

Completed·NNorthwestern University·Phase 1·NCT01280149·40 enrolled

2 more indications

ART1 trial

Substance P Challenge in Healthy Participants

Completed· GSK logo

GSK·N/A·NCT04676763·32 enrolled

ARB1 trial

Mechanism(s) Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 1

Terminated·VVanderbilt University Medical Center·Phase 4·NCT03738878·4 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Substance P. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Substance P compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Substance P. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: GSK

Substance P

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Headache1 trial

Angioedema1 trial

Type 1 Diabetes1 trial

Migraine1 trial

Antibody1 trial

ART1 trial

ARB1 trial

References

Drug Info

Quick Facts

Related News